Syros Pharmaceuticals has been granted a patent for compounds that selectively inhibit CDK7, inducing cellular apoptosis and inhibiting transcription of disease-related genes. The compounds can be used in treating various diseases, including cancers and fibrotic diseases. GlobalData’s report on Syros Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Syros Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Syros Pharmaceuticals's grant share as of February 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.
Cdk7 inhibitors for treating cancer and other diseases
The granted patent (Publication Number: US11918592B2) discloses a compound of Formula I and its various derivatives, including pharmaceutically acceptable salts, stereoisomers, or isotopic forms. The compound is designed to target aberrant activity of CDK7, offering a method for treating diseases associated with such activity. The patent covers a pharmaceutical composition comprising the compound and a method of administering it to patients suffering from proliferative diseases, infectious diseases, or diseases caused by expanded repeats of simple nucleotide tracts.
Furthermore, the patent details the specific diseases that can be targeted by the compound, including various types of cancers such as blood cancer, bone cancer, brain cancer, breast cancer, lung cancer, melanoma, neuroblastoma, and ovarian cancer. The method also includes the option of administering a second agent alongside the compound, which can be an anti-proliferative agent, an anti-cancer agent, an immunosuppressant, or a pain-relieving agent. Overall, the patent provides a comprehensive approach to treating a range of diseases associated with CDK7 activity, offering potential therapeutic options for patients with different types of conditions.
To know more about GlobalData’s detailed insights on Syros Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.